Product Images Oxaliplatin

This appears to be a table or graph of some sort, likely related to DFS (disease-free survival). There are probabilities listed from 0.0 to 1.0, and certain events or groups labeled as "Avowoxs" and "Bvervz" with their corresponding percentages. A hazard ratio and stratified log rank test are mentioned as well. The table includes a number of patients at risk over time (in months), but it is difficult to understand the full context without additional information.*

This appears to be a table displaying DFS (Disease-Free Survival) probability data for a medical study with two treatment arms (FOLFOX4 and LVSFU2) for patients with DUCES C colon cancer. The table lists different stages of the disease and their corresponding hazard ratios, as well as the DFS results in months. The Logrask Test showed a p-value of 0.005, indicating a statistically significant difference between the two treatment groups.*

This text provides information on the median survival and percentage of patients surviving after treatment with two different types of injections, Oxaliplatin Injection USP + 5-FULV and Oxaliplatin Injection USP + irinotecan. The median survival for the former was 19.4 months, while for the latter it was 17.6 months. The percentage of patients surviving was compared using the Log rank test, with a p-value of <0.0001*. The time frame for survival was observed up to 24 months, with the intervals of 3 months each.*

Oxaliplatin Injection is a medicine administered intravenously for patients requiring chemotherapy treatment. It is a sterile aqueous solution free from preservative, with 50mg/10mL dosage provided in a single-dose vial for each use. The package insert emphasizes the caution "contains cytotoxic agent" indicating that this medicine can cause cancer cells’ death. To avoid any adverse effects, patients must follow the instructions as given in the package insert. It is recommended to store it at 25°C (77°F), with excursions permitted between 15 to 30°C (59-86°F), protected from light, and away from children's reach. It is not recommended to use this medicine beyond its expiry date.*

The text includes information about a product called "Oxaliplatin Injection", available in two different concentrations of 50 mg/10mL and 50mg/20mL. Additionally, there are some codes mentioned: NOC 6718405081 and NDC 5718405081. The rest of the text seems to be a mix of random characters and does not provide any useful information.*

This is a description of a medication called oxaliplatin USP, which is contained in a vial with 100 mg of the substance and 20 mL of water for injection USP. The dosage and administration instructions should be found in a package insert. The medication should be stored at room temperature between 15 and 30 degrees Celsius and protected from light. The substance is also labeled as containing a cytotoxic agent. The string at the end could be a product code or lot number.*

The text contains some errors and is not fully readable, but it appears to be a label for Oxaliplatin Injection, USP containing the dosage and size information, and with some color specifications.*

This is a description of a medicine, specifically a cytotoxic agent called oxaliplatin USP 200mg, and how it should be stored and administered. The text also includes cautionary information, dosage instructions, and a warning not to freeze the medication.*

This appears to be a product label or information sheet for Oxaliplatin Injection, USP, in two different dosages: 200mg/10mL and 200mg/40mL of solution. It also includes a reference number (NOC 67184.0510), and some color codes (Pantone 157 C, Pantone Black C, and Pantone 7625). However, the beginning of the text is not clear and seems to contain abbreviations or syntax that cannot be correctly interpreted.*